D&M Company Holds Study Session and Shares Materials on FY2026 Medical Fee Revision – Sankei News

News Highlights

D&M Company conducted a study session and shared materials regarding the medical fee revision for FY2026. This initiative suggests several key points in medical M&A and business succession, including the importance of mid-to-long-term management and business succession strategies in anticipation of the revision cycle, the economies of scale through group participation, and the utilization of tax schemes, including conversion to specific medical corporations and social medical corporations.

Perspective from M&A Medical Editorial Department

The study session held by D&M Company in anticipation of the FY2026 medical fee revision should be viewed not merely as information sharing, but as a sign of strategic management decision-making. Since medical fee revisions directly impact the revenue structure of medical institutions, it is essential to incorporate them into mid-to-long-term business plans, and consequently, business succession plans, assuming the revision cycle (typically two years). In particular, group formation, aimed at maintaining facility standards and dispersing the burden of high-cost capital investments, is an effective means of enjoying economies of scale and maintaining/strengthening competitiveness. Furthermore, considering tax schemes with a view to transitioning to specific medical corporations or social medical corporations is a crucial point that should be examined in parallel with M&A to utilize preferential tax treatment and build a sustainable management foundation.

Key Issues Indicated by This News

• The necessity of early formulation of management and succession strategies in anticipation of the FY2026 revision.
• The benefits of maintaining facility standards and dispersing capital investment burdens through group formation.
• The importance of considering tax schemes with a view to transitioning to specific/social medical corporations.
• The concrete impact of medical fee revisions on business succession plans.

Practical Questions Arising from This News

• What specific content was shared in the materials during this study session?
• What scale and medical specialties of medical institutions is D&M Company targeting for group formation?
• What items are expected to be most significantly impacted by the FY2026 revision?

If You Feel “Should I Consult Too?”

Are you also making concrete plans for your institution regarding the FY2026 medical fee revision and future business succession? To minimize the impact of the revision and turn it into an opportunity, early strategic planning and consideration of options such as M&A or changes in corporate status are essential. It may be time to proceed with considerations based on expert knowledge, such as the economies of scale through group formation and the utilization of tax schemes.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics on a completely success-fee basis as an M&A support institution certified by the Small and Medium Enterprise Agency. Consultations are accepted with strict confidentiality. Free consultation here